scispace - formally typeset
E

Eve E. Slater

Researcher at Merck & Co.

Publications -  25
Citations -  2231

Eve E. Slater is an academic researcher from Merck & Co.. The author has contributed to research in topics: Insulin & Insulin receptor. The author has an hindex of 14, co-authored 25 publications receiving 2200 citations.

Papers
More filters
Journal ArticleDOI

Cloning of the gene and cDNA for mammalian β -adrenergic receptor and homology with rhodopsin

TL;DR: Cloning of the gene and cDNA for the mammalian β2AR indicates significant amino-acid homology with bovine rhodopin and suggests that, like rhodopsin7, βAR possesses multiple membrane-spanning regions.
Journal ArticleDOI

Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition.

TL;DR: Based on data from three studies with complete recording of adverse events in about 12,000 patients each, it was determined that angioedema in association with the angiotensin converting-enzyme inhibitor enalapril maleate occurred during the first week of therapy at the rate of one case per 3000 patients per week.
Journal ArticleDOI

Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells.

TL;DR: An inhibitor of the insulin receptor tyrosine kinase (IRTK), (hydroxy-2-naphthalenyl-methyl) phosphonic acid, was designed and synthesized and was shown to be an inhibitors of the biological effects of insulin in vitro.
Journal ArticleDOI

The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm in vivo.

TL;DR: Vanadate's insulin-mimetic effect on mouse diaphragm glycogenesis occurs at a site distal to the insulin receptor, suggesting that vanadate’s insulin-receptor activation by in vivo Vanadate administration is based on a conformational change in the receptor beta-subunit upon autophosphorylation.
Journal ArticleDOI

Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.

TL;DR: The objective in the clinical use of these inhibitors is to normalise plasma cholesterol levels in hypercholesterolaemic individuals, which contrasts with the profound reductions in cholesterol obtained when normocholesterolemic animals are treated by the high doses of these drugs required for toxicological assessment.